Afuco™ Anti-APP ADCC Therapeutic Antibody (Bapineuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Abeta. Bapineuzumab is a humanized monoclonal antibody that acts on the nervous system and may have potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-225 |
| Pricing | Inquiry |
| Host | Human |
| Target | APP |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FuncS, IF, Neut, ELISA, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |